Journal section: Oral Medicine and Pathology Publication Types: Research doi:10.4317/medoral.19387 http://dx.doi.org/doi:10.4317/medoral.19387

The clinical characteristics of benign oral mucosal tumors

Irit Allon 1, Ilana Kaplan 2, Gavriel Gal 3, Gavriel Chaushu 3, Dror M. Allon 3

- Department of Oral Pathology & Oral Medicine, Goldschleger School of Dental Medicine, Tel-Aviv University, Israel
- ² Institute of Pathology, Rabin Medical Center, Petah-Tikva, and Sackler School of Medicine, Tel-Aviv University, Israel
- ³ Departments of Oral and Maxillofacial Surgery, Rabin Medical Center, Petah-Tikva, and of Oral Surgery, Goldschleger School of Dental Medicine, Tel-Aviv University, Israel

Correspondence:
Department of Oral Pathology and Oral Medicine
School of Dental Medicine
Tel Aviv University, Tel Aviv
69978, Israel
alloniritl@gmail.com

Received: 13/06/2013 Accepted: 14/11/2013 Allon I, Kaplan I, Gal G, Chaushu G, Allon DM. The clinical characteristics of benign oral mucosal tumors. Med Oral Patol Oral Cir Bucal. 2014 Sep 1;19 (5):e438-43.

http://www.medicinaoral.com/medoralfree01/v19i5/medoralv19i5p438.pdf

Article Number: 19387 http://www.medicinaoral.com/
© Medicina Oral S. L. C.L.F. B 96689336 - pISSN 1698-4447 - eISSN: 1698-6946
eMail: medicina@medicinaoral.com
Indexed in:

Science Citation Index Expanded Journal Citation Reports Index Medicus, MEDLINE, PubMed Scopus, Embase and Emcare Indice Médico Español

Abstract

Objectives: To investigate the clinical characteristics and pre- biopsy provisional diagnoses of benign oral mucosal tumors.

Material and Methods: A 10- year retrospective analysis of all benign tumors of the oral mucosa, from a university- affiliated oral and maxillofacial surgery department.

Results: 146 benign tumors were included. The mean age was 49.6 years, with an approximately equal gender distribution. The most prevalent tumor types were lipomatous tumors (27.4%), vascular (23.3%), and salivary gland tumors (16.5%). Tongue, labial and buccal mucosa were the most frequently involved sites. The vast majority (98.6%) presented as non-ulcerated masses. Only 2 (1.4%) presented as ulcerated masses. The clinical provisional diagnosis correctly classified lesions as non-malignant in 93.3%. In only 9 (6.7%) suspicion of malignancy was included in the provisional diagnosis. However, benign neoplasia was unsuspected in 42.1% of tumors. These cases were clinically classified as reactive.

Conclusions: Benign tumors were most likely to be clinically correctly classified as non-malignant, but even in the setting of experienced oral surgeons, neoplasia was unsuspected in more than 40% of cases. This data strongly supports the need to biopsy every oral mucosal mass, since inaccurate clinical evaluation of the lesion's biological nature was a frequent event.

Key words: Malignant, benign, reactive, ulcerated mass, non-ulcerated mass, clinical diagnosis.

Introduction

The diagnosis of a wide range of lesions occurring in the oral mucosa is a vital part of dental practice. One of the main tools in developing a list of potential diagnosis for a lesion is knowledge of the frequency of each potential lesion type (1). This information can provide clinicians with the data to predict the probability of its occurrence. Unfortunately, information from the literature relating to the frequency of oral benign mucosal tumors is uncommon. Studies relating to benign tumors of the oral mucosa have been published in the literature, focusing on clinico-pathologic correlations of lipoma variants (2-5), salivary gland tumors (6-9), hemangiomas (10-12), neural (13-14) and other soft tissue mucosal tumors (15-21). Most of these do not relate directly to the clinical appearance and rate of ulceration of the tumors but rather, describe oral mucosal benign tumors as swellings or raised lesions. None of these studies investigated the accuracy of the pre-biopsy clinical in comparison to the final diagnosis. In text books and large scale screening studies benign tumors are described as raised masses or swellings (22-25), but a comprehensive analysis focusing on the spectrum of the benign oral mucosal tumors, including the clinical appearance and accuracy of the clinical differential diagnosis has not been found.

In a recently published 10-year retrospective analysis of malignant tumors of the oral mucosa, we found that close to 60% of oral malignancies presented as non-ulcerated masses, 20% presented as ulcerated masses and 12% as indurated ulcers (26). This pointed out that within the study sample, non-ulcerated masses rather than indurate ulcers were the most common clinical presentations of oral mucosalmalignancies. Another unexpected finding was that approximately one third of the oral mucosal malignancies were not suspected to be malignant prior to biopsy.

The aims of this study were to investigate the clinical characteristics and pre-biopsy provisional diagnoses of benign tumors of the oral mucosa.

Material and Methods

The study was conducted as a 10- year retrospective analysis. For the present study the archives of the Institute of Pathology of the Rabin Medical Center, Patah-Tikva, Israel were screened for benign tumors of the oral mucosa. The study included only diagnostic biopsies which were microscopically diagnosed as benign tumors, while those lacking information on clinical presentation were excluded. The pre-biopsy clinical differential diagnoses with which the biopsies were submitted were classified into reactive/ developmental lesions, benign tumors or malignancy, as previously described (27). In cases that included more than a single provisional diagnosis, the analysis included the classification which was the most severe possibility. There-

fore, in cases that included a request to rule out a malignancy, the clinical diagnosis included in the analysis was of malignancy. Being a university-affiliated institution training residents for national boards in oral and maxillofacial surgery, high clinical standards are implemented for clinical examination and reporting in patients' charts. All biopsies were performed by senior members of the department (GG, GC, DMA) with 9-35 years of experience, or by residents closely supervised by them. The study was approved by the institutional review board.

Results

During a 10-year period (2001-2011), a total of 146 benign tumors of the oral mucosa met the inclusion criteria (Fig. 1). There were 78 males and 68 females, representing an approximately equal gender distribution (Table 1).

The most prevalent tumor types were lipomatous tumors (27.4%), hemangioma variants (23.3%), and salivary gland tumors (16.5%). Other groups included neural and granular cell tumors (9.6% each), fibroblastic/myofibroblastic (7.6%), with the remaining classified as miscellaneous (Table 2). The age range was wide, (3 months-86 years) with a mean age of 49.6 years. The mean age at diagnosis of the lipomatous and salivary gland tumors was higher than that of the neural and fibroblastic/myofibroblastic tumors (over 50 and below 40 years, respectively) (Fig. 2).

The mobile tongue was the most frequently affected site (28.3%), followed by the labial mucosa (19.9%), buccal mucosa/vestibule (19.1%), hard palate (14.2%), gingiva/alveolar ridge (13.5%) and floor of mouth (4.3%). The lesion's size ranged between 2-40 mm, mean 10.5.

The vast majority (98.6%) of the benign tumors in the oral mucosa presented as a non-ulcerated masses (Table 3). Only 2 cases (1.4%) presented as ulcerated masses. These included one cavernous hemangioma of the lower lip in a 30 years old male and a granular cell tumor of the tongue in a 6 years old boy. The clinical description of ulceration was validated microscopically in both cases, and none of the cases in which ulceration had not been clinically described showed microscopic ulceration.

In regard to the pre-biopsy provisional diagnoses, 126 (93.3%) were correctly classified clinically as non-malignant, while only in 9 (6.7%) benign tumors arose suspicion for malignancy, (6.7% false negative) (Table 4). In 73 (57.9%) cases, the provisional diagnoses of a benign tumor was correct, while in 53(42.1%) benign neoplasia was an unsuspected finding, these cases were considered reactive lesions in the provisional diagnosis.

Discussion

The objective of the present study was to provide a comprehensive view of the spectrum of benign tumors of the




Fig. 1. The incidence of benign tumor groups in the oral mucosa.

Table 1. Benign tumors of the oral mucosa, clinical data.

Number of benign tumors	146	
	Lipomatous tumors 40 (27.4%)	
Diagnoses (n=146)	Vascular tumors 34 (23.3%)	
	Salivary gland tumors 24 (16.5%)	
	Neural tumors 14 (9.6%)	
	Granular cell tumors 14 (9.6%)	
	Fibroblastic/myofibroblastic lesions 11 (7.6%)	
	Miscellaneous tumors 9 (6%)	
M:F	78:68	
Age range, (years)	0.25-86, mean 49.6	
Site (n= 141)	Tongue 40 (28.3%)	
	Labial mucosa 28 (19.9%)	
	Buccal mucosa & vestibule 27 (19.1%)	
	Hard palate 20 (14.2%)	
	Gingiva/ridge/retromolar 19 (13.5%)	
	Floor of mouth 6 (4.3%)	
	Pterygomandibular raphe 1 (0.7%)	
Size range, (mm)	2-40, mean 10.5	


oral mucosa. Lipomatous, vascular (hemangioma) and salivary gland tumors, in descending order, were the most prevalent in this series. The tongue, labial and buccal mucosa were the most prevalent sites of presentation. There seemed to be differences in the age distribution between tumor groups: while neural tumors and fibroblastic/myofibroblastic tumors had a mean age under 40 years, lipomatous, vascular and salivary gland tumors presented a mean age between 54-63 years. However, there was a wide range with considerable overlap between the groups.

The size of benign tumors ranged between 2-40 mm in diameter for the entire study group. The salivary gland tumors presented the highest mean size (16.7 mm), while

the vascular and fibroblastic/myofibroblastic tumors presented the lowest mean size (7 and 8.1 mm respectively). Almost all the benign tumors included in the study presented as non- ulcerated masses. Only two presented as ulcerated masses and none as indurate ulcers or flat lesions. Most of the benign tumors were clinically classified correctly as non- malignant and did not raise any clinical suspicion for malignancy. However, more than forty percent of these benign tumors were clinically thought to be reactive, and did not raise suspicion of neoplasia. The results of the present series emphasize that the ulceration rate of benign oral mucosal tumors is very low, a feature that up till the present was described only in sporadic reports such as an ulcerated canalicular

Table 2. Clinical characteristics of the tumor groups involving oral mucosa.

Lipomatous tumors	n= 40 (27.4%)	Site (n=37)	
Fibrolipoma 26 (65%)	M:F 22:18 (1.2:1)	Buccal mucosa & vestibule 14 (37.8%)	
Lipoma 14 (35%)	Age: 44-84(years), mean 62.8	Tongue 10 (27%)	
	Size: 2-40 (mm), mean 10.5	Gingiva/ridge/retromolar 7 (19%)	
		Labial mucosa 6 (16.2%)	
Vascular tumors (hemangioma)	n= 34 (23.3%)	Tongue 12(35.3%)	
	M:F 19:15	Lower lip 11(32.3%)	
	Age: 8-86 (years), mean 54.6	Buccal mucosa 4 (11.8%)	
	Size: 3-15 (mm), mean 7	Alveolar ridge 4 (11.8%)	
		Hard palate 2 (5.9%)	
		Upper lip 1(2.9%)	
Salivary gland tumors	n=24 (16.5%)	Palate 13(54.2%)	
Pleomorphic adenoma 16 (66.7%)	M:F 11:13	Upper lip 4(16.7%)	
Cystadenoma 5(20.8%)	Age: 12-85(years), mean 56	Buccal mucosa/vestibule 4 (16.7%)	
Canalicular adenoma 2 (8.3%)	Size: 5-30 (mm), mean 16.9	Retromolar 2(8.3%)	
Myoepithelioma 1(4.2%)		Floor of mouth (4.1%)	
Neural tumors	n=14 (9.6%)	Lower lip 4(28.6%)	
Schwannoma 8 (57.2%)	M:F 11: 3	Gingiva 3(21.4%)	
Neurofibroma 4 (28.6%)	Age: 8-54(years), mean 32.9	Tongue 2(14.3%)	
Multiple neuroma 1(7.1%)	Size: 8-30(mm), mean 12.7	Floor of mouth 2(14.3%)	
Peripheral nerve sheath tumor		Buccal mucosa/ vestibule 2(14.3%)	
1(7.1%)		Hard palate 1(7.1%)	
Granular cell tumors	n=14 (9.6%)	Tongue 13 (92.9%)	
	M:F 5: 9	Floor of mouth 1 (7.1%)	
	Age: 6-77 (years), mean 47.6		
	Size: 5-35 (mm), mean 12.3		
Fibroblastic/myofibroblastic	n=11(7.6%)	Palate: 3 (27.2%)	
tumors	M:F 7:4	Buccal mucosa 3 (27.2%)	
Myofibroma 4(36.4%)	Age: 2-54 (years), mean 38.4	Floor of mouth 2 (18.3%)	
Fibroma (true) 3(27.2%)	Size: 3-30 (mm), mean 8.1	Pterygomandibular raphe 1(9.1%)	
Nodular fasciitis 2 (18.2%)		Gingiva: 1(9.1%)	
Collagenous fibroma 1(9.1%)		Lower lip: 1(9.1%)	
Solitary fibrous tumor 1(9.1%)	0 (60()		
Miscellaneous tumors	n=9 (6%)	Gingiva 4	
Leiomyoma 3	M:F 3:6	Tongue 3	
Peripheral odontogenic fibroma 3	Age: 3-82, mean 42.3	Lower lip 1	
Angiokeratoma 2	Size: 7-30, mean 15.7	Palate 1	
Ectomesenchymal chondromyxoid			
tumor of tongue 1			



 $\textbf{Fig. 2.} \ \ \text{Mean age at diagnosis of benign tumors in the oral mucosa}.$

Table 3. The frequency of ulceration in benign tumors.

Type of benign tumor	Non-ulcerated mass	Ulcerated mass
Lipomatous	40(100%)	-
Vascular	33 (97%)	1 (3%)
Salivary gland	24 (100%)	-
Neural	14 (100%)	-
Granular cell	13 (92.9%)	1 (7.1%)
Fibroblastic/myofibroblastic	11 (100%)	_
Miscellaneous	9 (100%)	-
Total benign tumors (n=146)	144(98.6%)	2(1.4%)

Table 4. The accuracy of provisional clinical diagnosis, classification as benign or malignant.

Final Diagnosi	Clinical Differential Diagnosis	
Final Diagnosi	Malignant	Non-malignant
Lipomatous tumors	-	38(100%)
Vascular tumors	1(3%)	32(97%)
Salivary gland tumors	1(5%)	19(95%)
Neural tumors	3(21.4%)	11(78.6%)
Granular cell tumors	1(7.7%)	12(92.3%)
Fibroblastic/myofibroblastic tumors	2(20%)	8(80%)
Miscellaneous tumors	1(14.3%)	6(85.7%)
Total (n=135)	9(6.7%)	126(93.3%)

adenoma from the palate (8-9) or an ulcerated myofibroblastic tumor (16).

This study follows a previous study on malignancies of the oral mucosa (26). When comparing the results of the present study to those from the malignant oral mucosal tumors, performed in the same center and same time period, it is evident that while in the benign tumors 98% presented as non-ulcerated masses, in the malignant group there was a significantly higher fraction presenting as ulcerated masses (20.4%) or indurate ulcers (11.9%), although still more than half (59.7%) of the malignancies were non-ulcerated at presentation (26). These differences were statistically significant (p<0.001, chi-square).

When considering the pre-biopsy classification as malignant or non-malignant lesions (reactive, developmental or benign tumors), the accuracy was significantly higher in the benign tumor group (93.3%), compared with only 68.9% in the malignant tumor group. This implies a significantly higher fraction of false negatives in clinical identification of malignancies (31.1% in the malignant compared to 6.7% in benign groups, p<0.001, chisquare). Interestingly, the percent of unsuspected neoplasia in the benign tumors (42.1%), was quite similar to the percent of unsuspected malignancy in the malignant tumor group (31.1%). The data presented was obtained from a medical teaching center and even in this context of highly skilled clinicians, 31.1-42.1% of both malignant and benign neoplasia where unsuspected as such

prior to biopsy. This highlights the fact that the ability to recognize a neoplasm on a clinical basis is quite limited. Since non- ulcerated masses are the typical presentation of almost all benign mucosal tumors (present results), more than half of the malignant tumors (26) and the majority of reactive lesions (27), the ability to predict the true biological nature of oral mucosal masses using visual inspection alone is relatively poor, thus, diagnostic biopsy stays an essential and mandatory tool for diagnosis of all masses of oral mucosa. Although the majority of mucosal masses would turn out to be reactive following microscopic analysis, they must not be ignored since both benign and malignant neoplasms cannot be differentiated clinically from reactive lesions with a high degree of confidence. In the decision whether a mass should be removed and submitted for analysis. or followed-up, the allusive "clinical judgment" should play a minimal role. There should be stronger emphasis on the need to biopsy every oral mass, regardless of its ulceration status.

A few possible explanations to the different rate of ulceration between benign and malignant tumors may be proposed: size-related, site- related and biological aspects. Regarding the size, it is possible that as lesions grow they interfere with anatomical structures, compromise the blood supply, or may become traumatized during functional movements such as mastication and speech and therefore ulcerate. However, there was a significant overlap in the size range between the be-

nign and malignant groups (2-40 mm versus 5-30 mm respectively), therefore, size alone would not be a contributing factor for ulceration.

Regarding the site, it is possible that lesions appearing in specific sites may be easily traumatized. However, the tongue was the most common site for both malignant (26) and benign tumors (present study), so it appears that the site distribution cannot offer an adequate explanation for the difference in the clinical presentation. Therefore, additional contributing factors related to the different biological characteristics of the tumors may possibly account for the differences. Within the group of malignancies, there were also differences between the tumor types in the tendency to become ulcerated: SCC ulcerated more frequently than other tumor types, supporting the assumption that differences probably result from variations in biological characteristics (26).

In conclusion, the clinical ability to recognize benign mucosal neoplasms by visual inspection is relatively poor. In about 40% of the benign mucosal tumors, neoplasia was clinically unsuspected, thus, the need to biopsy every oral mucosal mass is supported.

References

- 1. Matranga D, Di fede O, Paderni C, Albanese A, Pizzo G, Magro R, et al. Demographic and behavioural profiles of patients with oral mucosal lesions by a homogeneity analysis. Oral Dis. 2012;18:396-401.
- 2. Manor E, Sion-vardy N, Joshua BZ, Bodner L. Oral lipoma: analysis of 58 new cases and review of the literature. Ann DiagnPathol. 2011:15:257-61.
- 3. Furlong MA, Fanburg-smith JC, Childers EL. Lipoma of the oral and maxillofacial region: Site and subclassification of 125 cases. Oral Surg Oral Med Oral Pathol Oral RadiolEndod. 2004;98:441-50.
- 4. Chandrashekhar P, Jose M, Dadhich M, Chatra L, Holla V. Spindle cell lipoma: a case report and review of literature. Kathmandu Univ Med J (KUMJ). 2012;10:92-5.
- 5. Said-al-naief N, Zahurullah FR, Sciubba JJ. Oral spindle cell lipoma. Ann DiagnPathol. 2001:5:207-15.
- 6. Nikitakis NG, Argyris P, Sklavounou A, Ppapadimitriou JC. Oral myoepithelioma of soft tissue origin: report of a new case and literature review. Oral Surg Oral Med Oral Pathol Oral RadiolEndod. 2010:110:e48-51.
- 7. Nag D, Biswas PK, Mandal PK, Bhattacharyya NK, Gautam D, Mukhopadhyay S. Tumours of minor salivary glands--a clinicopathologic study. J Indian Med Assoc. 2012:110:567-577.
- 8. Yuce S, Uysal IÖ, Dogan M, Ersin T, Muderris S. Canalicular adenoma of the palate. J Craniofac Surg. 2012:23:e396-8.
- 9. Smullin SE, Fielding AF, Susarala SM, Pringle G, Eichstaedt R. Canalicular adenoma of the palate: case report and literature review. Oral Surg Oral Med Oral Pathol Oral RadiolEndod. 2004:98:32-6.
- 10. de Oliveira DH, da Silveira EJ, de Medeiros AM, Alves PM, Queiroz LM. Study of the etiopathogenesis and differential diagnosis of oral vascular lesions by immunoexpression of GLUT-1 and HIF-1α. J Oral Pathol Med. 2014;43:76-80.
- 11. Bharti V, Singh J. Capillary hemangioma of palatal mucosa. J Indian SocPeriodontol. 2012;16:475-8.
- 12. Reich RF, Moss S, Freedman PD. Intranodalhemangioma of the oral soft tissues: a case report of a rare entity with review of the literature. Oral Surg Oral Med Oral Pathol Oral RadiolEndod. 2000:90:71-3.
- 13. Rozza-de-Menezes RE, Andrade RM, Israel MS, Gonçalves Cunha KS. Intraoral nerve sheath myxoma: case report and systematic review of the literature. Head Neck. 2013;35:E397-404.
- 14. Gonzalez-Arriagada WA, Leon JE, Vargas PA, Paesde Almeida O,

- Lopes MA. Intraoral sclerosing perineurioma: a case report and review of the literature. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2010:109:e46-52.
- 15. Gueiros LA, Romanach MJ, Pires-Soubhia AM, Pires FR, Paes-de-Almeida O, Vargas PA. Angioleiomyoma affecting the lips: report of 3 cases and review of the literature. Med Oral Patol Oral Cir Bucal. 2011:16:e482-7.
- 16. Vered M, Allon I, Buchner A, Dayan D. Clinico-pathologic correlations of myofibroblastic tumors of the oral cavity. II. Myofibroma and myofibromatosis of the oral soft tissues. J Oral Pathol Med. 2007;36:304-14.
- 17. Epivatianos A, Iordanidis S, Zaraboukas T. Myxoma of the oral soft tissues: Report of a case and literature review. J Oral Maxillofac Surg. 2007:65:317-20.
- 18. Alawi F, StrattonD, Freedman PD. Solitary fibrous tumor of the oral soft tissues: a clinicopathologic and immunohistochemical study of 16 cases. Am J SurgPathol. 2001;25:900-10.
- 19. Elzay RP, Dutz W. Myxomas of the paraoral-oral soft tissues. Oral Surg Oral Med Oral Pathol. 1978;45:246-54.
- 20. Pandey P, Chaudhary CP, Ansari AA, Singh R. Intramucosal nevus of buccal mucosa in a male child. BMJ Case Rep. 2013;25:2013.
- 21. Shah SS, Kurago ZB. Unusual papillary lesion of the ventral tongue: case report of solitary angiokeratoma of the oral cavity. N Y State Dent J. 2013;79:46-9.
- 22. Bouquot JE, Gundlach KK. Oral exophytic lesions in 23,616 white Americans over 35 years of age. Oral Surg Oral Med Oral Pathol. 1986:62:284-91.
- 23. Bouquot JE. Common oral lesions found during a mass screening examination. J Am Dent Assoc. 1986:112:50-7.
- 24. Shira RB. Diagnosis of common lesions of the oral cavity. J Oral Surg (Chic). 1957;15:95-119.
- 25. Ross NM, GrossE. Oral findings based on an automated multiphasic health screening program. J Oral Med. 1971:26:21-6.
- 26. Allon I, Allon DM, Gal G, Anavi Y, Chaushu G, Kaplan I. Re-evaluation of common paradigms regarding the clinical appearance of oral mucosal malignancies. J Oral Pathol Med. 2013;42:670-5.
- 27.Allon I, Allon DM, Anavi Y, Kaplan I. The Significance of Surface Ulceration as a Sign of Malignancy in Exophytic Oral Mucosal Lesions: Myth or Fact?. Head Neck Pathol. 2013;7:149-54.

Conflict of Interest

The authors declare no conflict of interest. Competing interests: None declared, Funding: None, Ethical approval: Not required, Patient consent: Not required.

*IA and IK contributed equally.